A
Amy Chadburn
Researcher at NewYork–Presbyterian Hospital
Publications - 76
Citations - 8923
Amy Chadburn is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Lymphoma & T cell. The author has an hindex of 34, co-authored 76 publications receiving 8452 citations. Previous affiliations of Amy Chadburn include New York University & Cornell University.
Papers
More filters
Journal ArticleDOI
Accumulation of miR-155 and BIC RNA in human B cell lymphomas
Peggy S. Eis,Wayne Tam,Liping Sun,Amy Chadburn,Zongdong Li,Mario Gomez,Elsebet Lund,James E. Dahlberg +7 more
TL;DR: It is found that clinical isolates of several types of B cell lymphomas, including diffuse large B Cell lymphoma (DLBCL), have 10- to 30-fold higher copy numbers of miR-155 than do normal circulating B cells, and the quantities of BIC RNA are elevated in lymphoma cells, but ratios of the amounts of the two RNAs are not constant, suggesting that the level of mi R-155 is controlled by transcription and processing.
Journal ArticleDOI
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.
TL;DR: It is recommended that these malignant lymphomas be designated primary effusion lymphomas (PEL), rather than body cavity-based lymphomas, since this term describes them more accurately and avoids their confusion with other malignant cancerous lymphomas that occur in the body cavities.
Journal ArticleDOI
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
Daniel M. Knowles,Ethel Cesarman,Amy Chadburn,Glauco Frizzera,Jonathan M. Chen,Eric A. Rose,Robert E. Michler +6 more
TL;DR: The posttransplantation lymphoproliferative disorders are divisible into three categories exhibiting distinct morphologic and molecular genetic characteristics and Alterations involving the N-ras and c-myc proto- oncogenes and the p53 tumor suppressor gene may play an important role in the development and/or progression of the PT-LPDs.
Journal ArticleDOI
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
Lawrence D. Kaplan,Jeannette Y. Lee,Richard F. Ambinder,Joseph A. Sparano,Ethel Cesarman,Amy Chadburn,Alexandra M. Levine,David T. Scadden +7 more
TL;DR: The addition of rituximab to CHOP in patients with HIV-NHL may be associated with improved tumor responses, however, these benefits may be offset by an increase in infectious deaths, particularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3).
Journal ArticleDOI
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin,Amy Chadburn,Paul J. Christos,Karen Weil,Richard R. Furman,Jia Ruan,Rebecca Elstrom,Ruben Niesvizky,Scott Ely,Maurizio DiLiberto,Ari Melnick,Daniel M. Knowles,Selina Chen-Kiang,Morton Coleman,John P. Leonard +14 more
TL;DR: In selected asymptomatic patients with MCL, deferred initial treatment ("watch and wait") is an acceptable management approach and time to treatment did not predict overall survival in a multivariate analysis.